Skip to main content
SpringerLink
Log in

Molecular Pathology and Cytogenetics of Endometrial Carcinoma, Carcinosarcoma, and Uterine Sarcomas

  • Chapter
Uterine Cancer

Abstract

Uterine neoplasms include epithelial cancers (endometrial carcinomas and carcinosarcomas) and mesenchymal neoplasms (leiomyosarcomas and endometrial stromal sarcomas). The epithelial cancers occur much more frequently than uterine mesenchymal tumors, and hence more information is available on their molecular pathology. Carcinosarcoma of the uterus previously considered as mixed neoplasms with stromal and epithelial elements is now classified as high-grade endometrial carcinoma on the basis of genetic and molecular characteristics. This chapter will describe the molecular and cytogenetic features of uterine cancers.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 149.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15(1):10–7.

    Article  CAS  PubMed  Google Scholar 

  2. Liu F-S. Molecular carcinogenesis of endometrial cancer. Taiwan J Obstet Gynecol. 2007;46(1):26–32.

    Article  CAS  PubMed  Google Scholar 

  3. Sherman ME, Bur ME, Kurman RJ. p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis. Hum Pathol. 1995;26(11):1268–74.

    Article  CAS  PubMed  Google Scholar 

  4. Matias-Guiu X, Catasus L, Bussaglia E, et al. Molecular pathology of endometrial hyperplasia and carcinoma. Hum Pathol. 2001;32:569–77.

    Article  CAS  PubMed  Google Scholar 

  5. Llobet D, Pallares J, Yeramian A, et al. Molecular pathology of endometrial carcinoma; practical aspects from the diagnostic and therapeutic viewpoints. J Clin Pathol. 2009;62:777–85.

    Article  CAS  PubMed  Google Scholar 

  6. Matias‐Guiu X, Prat J. Molecular pathology of endometrial carcinoma. Histopathology. 2013;62:111–23.

    Article  PubMed  Google Scholar 

  7. Cancer Genome Atlas Research Network, Kandoth C, Schultz N, Cherniack AD, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497(7447):67–73.

    Article  Google Scholar 

  8. Caduff RF, Johnston CM, Svoboda-Newman SM, et al. Clinical and pathological significance of microsatellite instability in sporadic endometrial carcinoma. Am J Pathol. 1996;148:1671–8.

    PubMed Central  CAS  PubMed  Google Scholar 

  9. Weng LP, Smith WM, Dhalia P, et al. PTEN suppresses breast cancer cell growth by phosphatase activity-dependent G1 arrest followed by cell death. Cancer Res. 1999;59:5808–14.

    CAS  PubMed  Google Scholar 

  10. Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997;275:1943–7.

    Article  CAS  PubMed  Google Scholar 

  11. Janiec-Jankowska A, Konopka B, Goluda C, et al. TP53 mutations in endometrial cancers. Int J Gynecol Cancer. 2010;20(2):196–202.

    Article  PubMed  Google Scholar 

  12. Ellis PE, Ghaem-Maghami S. Molecular characteristics and risk factors in endometrial cancer. Int J Gynecol Cancer. 2010;20(7):1207–16.

    Article  PubMed  Google Scholar 

  13. Ahmed Q, Alosh B, Bandyopadhyay S, Ali-Fehmi R. Gynecologic cancers: molecular updates. Clin Lab Med. 2013;33(4):911–25.

    Article  PubMed  Google Scholar 

  14. Lax SF. Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification. Virchows Arch. 2004;444(3):213–23.

    Article  CAS  PubMed  Google Scholar 

  15. Bussagalia E, del Rio E, Matias-Guiu X, et al. PTEN mutations in endometrial carcinomas: a molecular and clinicopathologic analysis of 38 cases. Hum Pathol. 2000;31:312–7.

    Article  Google Scholar 

  16. Kapucuoglu N, Aktepe F, Kaya H, et al. Immunohistochemical expression of PTEN in normal, hyperplastic and malignant endometrium and its correlation with hormone receptors, bcl-2, bax, and apoptotic index. Pathol Res Pract. 2007;203:153–62.

    Article  CAS  PubMed  Google Scholar 

  17. Terakawa N, Kanamori Y, Yoshida S. Loss of PTEN expression followed by Akt phosphorylation is a poor prognostic factor for patients with endometrial cancer. Endocr Relat Cancer. 2003;10:203–8.

    Article  CAS  PubMed  Google Scholar 

  18. Salvesten HB, Stefansson I, Kretzschmar EI, et al. Significance of PTEN alterations in endometrial carcinoma: a population-based study of mutations, promoter methylation and PTEN protein expression. Int J Oncol. 2004;25:1615–23.

    Google Scholar 

  19. Wolf J, Slomovitz BM. Novel biologic therapies for the treatment of endometrial cancer. Int J Gynecol Cancer. 2005;15:411–2.

    Article  Google Scholar 

  20. Oza M, Elit L, Biagi J, et al. Molecular correlates associated with a phase II study of temsirolimus (CCI-779) in patients with metastatic or recurrent endometrial cancer: NCIC IND 160. 2006 ASCO Annual Meeting Proceedings (Post-meeting edition), J Clin Oncol; 2006. p. 24.

    Google Scholar 

  21. Enomoto T, Fujita M, Inoue M, et al. Alterations of the p53 tumour suppressor gene and its association with activation of the c-K-ras protooncogene in pre-malignant and malignant lesions of the human endometrium. Cancer Res. 1993;53:1883–8.

    CAS  PubMed  Google Scholar 

  22. Sakasi H, Nisi I, Takahoshith H, et al. Mutation of the k-ras protooncogene in endometrial hyperplasia and carcinoma. Cancer Res. 1993;53:1906–10.

    Google Scholar 

  23. Lagarda H, Catasus L, Arg€ uelles R, Matias-Guiu X, Prat J. K- ras mutations in endometrial carcinoma with microsatellite instability. J Pathol. 2001;193:193–9.

    Article  CAS  PubMed  Google Scholar 

  24. Moreno-Bueno G, Sanchez-Estevez C, Palacios J, Hardisson D, Shiozawa T. Low frequency of BRAF mutations in endometrial and in cervical carcinomas. Clin Cancer Res. 2006;15:3865–6.

    Article  Google Scholar 

  25. Pallares J, Velasco A, Eritja N, et al. Promoter hypermethylation and reduced expression of RASSF1A are frequent molecular alterations of endometrial carcinoma. Mod Pathol. 2008;21:691–9.

    Article  CAS  PubMed  Google Scholar 

  26. Oda K, Stokoe D, Taketani Y, et al. High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res. 2005;65:10669–73.

    Article  CAS  PubMed  Google Scholar 

  27. Machin P, Catasus L, Pons C, et al. CTNNB1 mutations and beta-catenin expression in endometrial carcinomas. Hum Pathol. 2002;33:206–12.

    Article  CAS  PubMed  Google Scholar 

  28. Saegusa M, Hashimura M, Yoshida T, et al. β-catenin nuclear accumulation and aberrant nuclear expression during endometrial tumorigenesis. Br J Cancer. 2001;84:209–17.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  29. Gatius S, Velasco A, Azueta A, et al. FGFR-2 alterations in endometrial carcinoma. Mod Pathol. 2011;24:1500–10.

    Article  CAS  PubMed  Google Scholar 

  30. Hayes MP, Ellenson LH. Molecular alterations in uterine serous carcinoma. Gynecol Oncol. 2010;116:286–9.

    Article  CAS  PubMed  Google Scholar 

  31. Tashiro H, Isacson C, Levine R, et al. p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am J Pathol. 1997;150:177–85.

    PubMed Central  CAS  PubMed  Google Scholar 

  32. Horree N, van Diest P, van der Groep P, et al. Progressive derailment of cell cycle regulators in endometrial carcinogenesis. J Clin Pathol. 2008;61:36–42.

    Article  CAS  PubMed  Google Scholar 

  33. Kalogiannidis I, Bobos M, Papanikolaou A, et al. Immunohistochemical bcl-2 expression, p53 overexpression, PR and ER status in endometrial carcinoma and survival outcomes. Eur J Gynaecol Oncol. 2008;29:19–25.

    CAS  PubMed  Google Scholar 

  34. Villela J, Cohen S, Smith S, et al. HER-2/neu overexpression in uterine papillary serous cancer and its possible therapeutic implication. Int J Gynecol Cancer. 2006;16:1897–902.

    Article  Google Scholar 

  35. Roses R, Paulson E, Sharma A, et al. HEU-2/neu over expression as a predictor for the transition from in situ to invasive breast cancer. Cancer Epidemiol Biomarkers Prev. 2009;18:1386–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  36. Hogdall E, Christensen L, Kjaer S, et al. Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer study. Cancer. 2003;98:66–73.

    Article  CAS  PubMed  Google Scholar 

  37. Saffari B, Jones L, El-Naggar A, et al. Amplification and overexpression of HER-2/neu (c-erbB2) in endometrial cancers: correlation with overall survival. Cancer Res. 1995;55:5693–8.

    CAS  PubMed  Google Scholar 

  38. Slomovitz B, Broaddus R, Burke T, et al. Her2/neu overexpression and amplification in uterine papillary serous carcinoma. J Clin Oncol. 2004;22:3126–32.

    Article  CAS  PubMed  Google Scholar 

  39. Fleming G, Sill M, Darcy K, et al. Phase II trial of trastuzumab in women with advanced or recurrent HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2010;116:15–20.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  40. Sakuragi N, Nishiya M, Ikeda K, et al. Decreased E-cadherin expression in endometrial carcinoma is associated with tumour differentiation and deep myometrial invasion. Gynecol Oncol. 1994;53:183–9.

    Article  CAS  PubMed  Google Scholar 

  41. Moreno-Bueno G, Hardisson D, Sarrio D, et al. Abnormalities of E- and P-cadherin and catenin (A-F-catenin and p120ctn) expression in endometrial cancer and endometrial atypical hyperplasia. J Pathol. 2003;199:471–8.

    Article  CAS  PubMed  Google Scholar 

  42. Tsikouras P, Bouchlariotou S, Vrachnis N, Dafopoulos A, Galazios G, Csorba R, et al. Endometrial cancer: molecular and therapeutic aspects. Eur J Obstet Gynecol Reprod Biol. 2013;169(1):1–9.

    Article  CAS  PubMed  Google Scholar 

  43. Hayes MP, Douglas W, Ellenson LH. Molecular alterations of EGFR and PIK3CA in uterine serous carcinoma. Gynecol Oncol. 2009;113:370–3.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  44. Leslie KK, Laidler L, Albitar L, et al. Tyrosine kinase inhibitors in endometrial cancer. Int J Gynecol Cancer. 2005;15:409–11.

    Article  Google Scholar 

  45. Tritz D, Pieretti M, Turner S, Powell D. Loss of heterozygosity in usual and special variant carcinomas of the endometrium. Hum Pathol. 1997;28:607–12.

    Article  CAS  PubMed  Google Scholar 

  46. Cao QJ, Belbin T, Socci N, et al. Distinctive gene expression profiles by cDNA microarrays in endometrioid and serous carcinomas of the endometrium. Int J Gynecol Pathol. 2004;23:321–9.

    Article  PubMed  Google Scholar 

  47. Schwab CL, Bellone S, English DP, et al. Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo. Br J Cancer. 2014;111(9):1750–6.

    Article  CAS  PubMed  Google Scholar 

  48. Aghajanian C, Sill MW, Darcy KM, Greer B, McMeekin DS, Rose PG, et al. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2011;29(16):2259–65.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  49. Aertgeerts K, Skene R, Yano J, Sang BC, Zou H, Snell G, et al. Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2. J Biol Chem. 2011;286:18756–65.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  50. Leslie KK, Sill MW, Lankes HA, Edgar G, Godwin AK, Gray H, et al. Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer. Gynecol Oncol. 2012;127(2):345–50.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  51. Leslie KK, Sill MW, Fischer E, Darcy KM, Mannel RS, Tewari KS, et al. A phase II evaluation of Gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2013;129(3):486–94.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  52. Konecny GE, Kolarova T, O’Brien NA, Winterhoff B, Yang G, Qi J, et al. Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells. Mol Cancer Ther. 2013;12(5):632–42.

    Article  CAS  PubMed  Google Scholar 

  53. Schuler KM, Rambally BS, DiFurio MJ, et al. Antiproliferative and metabolic effects of metformin in a preoperative window clinical trial for endometrial cancer. Cancer Med. 2014. doi:10.1002/cam4.353. [Epub ahead of print].

  54. Wada H, Enomto T, Fujita M, et al. Molecular evidence that most but not all carcinosarcomas of the uterus are combination tumors. Cancer Res. 1997;57:5379–85.

    CAS  PubMed  Google Scholar 

  55. Zeisberg M, Neilson EG. Biomarkers for epithelial–mesenchymal transitions. J Clin Invest. 2009;119:1429–37.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  56. McConechy MK, Ding J, Cheang MC, et al. Use of mutation profiles to refine the classification of endometrial carcinomas. J Pathol. 2012;228:20–30.

    PubMed Central  CAS  PubMed  Google Scholar 

  57. Castilla MA, Moreno-Bueno G, Romero-Pérez L, et al. Micro-RNA signature of the epithelial-mesenchymal transition in endometrial carcinosarcoma. J Pathol. 2011;223:72–80.

    Article  CAS  PubMed  Google Scholar 

  58. Perot G, Croce S, Ribeiro A, et al. Med12 alterations in both human benign and malignant uterine soft tissue tumors. PLoS One. 2012;7, e40015.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  59. Chiang S, Oliva E. Recent developments in uterine mesenchymal neoplasms. Histopathology. 2013;62(1):124–37.

    Article  PubMed  Google Scholar 

  60. Kobayashi H, Uekuri C, Akasaka J, Ito F, Shigemitsu A, Koike N, et al. The biology of uterine sarcomas: a review and update. Mol Clin Oncol. 2013;1(4):599–609.

    PubMed Central  PubMed  Google Scholar 

  61. Mittal KR, Chen F, Wei JJ, et al. Molecular and immunohistochemical evidence for the origin of uterine leiomyosarcomas from associated leiomyoma and symplastic leiomyoma-like areas. Mod Pathol. 2009;22:1303–11.

    Article  CAS  PubMed  Google Scholar 

  62. Ip PPC, Cheung ANY. Pathology of uterine leiomyosarcomas and smooth muscle tumours of uncertain malignant potential. Best Pract Res Clin Obstet Gynaecol. 2011;25(6):691–704.

    Article  PubMed  Google Scholar 

  63. Makinen N, Mehine M, Tolvanen J, et al. Med12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas. Science. 2011;334:252–5.

    Article  PubMed  Google Scholar 

  64. Matsubara A, Sekine S, Yoshida M, et al. Prevalence of Med12 mutations in uterine and extrauterine smooth muscle tumors. Histopathology. 2013;62(4):657–61.

    Article  PubMed  Google Scholar 

  65. Makinen N, Heinonen HR, Moore S, Tomlinson IP, van der Spuy ZM, Aaltonen LA. Med12 exon 2 mutations are common in uterine leiomyomas from South African patients. Oncotarget. 2011;2:966–9.

    PubMed Central  PubMed  Google Scholar 

  66. Danielson LS, Menendez S, Attolini CS, et al. A differentiation based microRNA signature identifies leiomyosarcoma as a mesenchymal stem cell-related malignancy. Am J Pathol. 2010;177:908–17.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  67. Mansi JL, Ramachandra S, Wiltshaw E, Fisher C. Endometrial stromal sarcomas. Gynecol Oncol. 1990;36:113–8.

    Article  CAS  PubMed  Google Scholar 

  68. Tavassoli FA, Devilee P. World Health Organization classification of tumours. Pathology and genetics of tumours of the breast and female genital organs. Lyon: IARC Press; 2003.

    Google Scholar 

  69. Chiang S, Oliva E. Cytogenetic and molecular aberrations in endometrial stromal tumors. Hum Pathol. 2011;42(5):609–17.

    Article  CAS  PubMed  Google Scholar 

  70. Dal Cin P, Talcott J, Abrams J, Li FP, Sandberg AA. Ins(10;19) in an endometrial stromal sarcoma. Cancer Genet Cytogenet. 1988;36:1–5.

    Article  CAS  PubMed  Google Scholar 

  71. Sreekantaiah C, Li FP, Weidner N, Sandberg AA. An endometrial stromal sarcoma with clonal cytogenetic abnormalities. Cancer Genet Cytogenet. 1991;55:163–6.

    Article  CAS  PubMed  Google Scholar 

  72. Li H, Wang J, Mor G, Sklar J. A neoplastic gene fusion mimics trans-splicing of RNAs in normal human cells. Science. 2008;321:1357–61.

    Article  CAS  PubMed  Google Scholar 

  73. Koontz JI, Soreng AL, Nucci M, et al. Frequent fusion of the JAZF1 and JJAZ1 genes in endometrial stromal tumors. Proc Natl Acad Sci U S A. 2001;98:6348–53.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  74. Chiang S, Castilla MA, Palacios J, et al. Microrna expression profiling of low-grade endometrial stromal sarcomas and undifferentiated endometrial sarcomas. Mod Pathol. 2012;25:263A.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gynecological Oncology, Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwavidyapeetham, Kochi, India

    Anupama Rajanbabu MD, MRCOG

Authors
  1. Anupama Rajanbabu MD, MRCOG
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anupama Rajanbabu MD, MRCOG .

Editor information

Editors and Affiliations

  1. Obstetrics and Gynecology, University College of Medical Sciences, New Delhi, India

    Shalini Rajaram

  2. Surgical &Gynec Oncology, Lakeshore & Welcare Hospitals, Kochi, Kerala, India

    Chitrathara K

  3. Gynec Onclogy, Tata Memorial Hospital, Mumbai, India

    Amita Maheshwari

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer India

About this chapter

Cite this chapter

Rajanbabu, A. (2015). Molecular Pathology and Cytogenetics of Endometrial Carcinoma, Carcinosarcoma, and Uterine Sarcomas. In: Rajaram, S., K, C., Maheshwari, A. (eds) Uterine Cancer. Springer, New Delhi. https://doi.org/10.1007/978-81-322-1892-0_2

Download citation

  • DOI: https://doi.org/10.1007/978-81-322-1892-0_2

  • Publisher Name: Springer, New Delhi

  • Print ISBN: 978-81-322-1891-3

  • Online ISBN: 978-81-322-1892-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation